Department of Clinical and Molecular Endocrinology and Oncology, University of Naples Federico II, Italy.
Eur J Endocrinol. 2012 Nov;167(5):609-18. doi: 10.1530/EJE-12-0627. Epub 2012 Sep 6.
Heart failure (HF) is a major cause of morbidity and mortality in Europe and in the United States. The aim of this review article was to assess the results of the prospective studies that evaluated the risk of HF in patients with overt and subclinical thyroid disease and discuss the mechanism of this dysfunction.
Reports published with the following search terms were searched:, thyroid, hypothyroidism, hyperthyroidism, subclinical hyperthyroidism, subclinical hypothyroidism, levothyroxine, triiodothyronine, antithyroid drugs, radioiodine, deiodinases, clinical symptoms, heart rate, HF, systolic function, diastolic function, systemic vascular resistance, endothelial function, amiodarone and atrial fibrillation. The investigation was restricted to reports published in English.
The outcome of this analysis suggests that patients with untreated overt thyroid dysfunction are at increased risk of HF. Moreover, persistent subclinical thyroid dysfunction is associated with the development of HF in patients with serum TSH <0.1 or > 10 mU/l.
The timely recognition and effective treatment of cardiac symptoms in patients with thyroid dysfunction is mandatory because the prognosis of HF may be improved with the appropriate treatment of thyroid dysfunction.
心力衰竭（HF）是欧洲和美国发病率和死亡率的主要原因。本文旨在评估评估显性和亚临床甲状腺疾病患者发生 HF 的风险的前瞻性研究结果，并讨论这种功能障碍的发生机制。
使用以下搜索词搜索发表的报告：甲状腺、甲状腺功能减退症、甲状腺功能亢进症、亚临床甲状腺功能亢进症、亚临床甲状腺功能减退症、左甲状腺素、三碘甲状腺原氨酸、抗甲状腺药物、放射性碘、脱碘酶、临床症状、心率、HF、收缩功能、舒张功能、全身血管阻力、内皮功能、胺碘酮和心房颤动。该研究仅限于英文报告。
这项分析的结果表明，未经治疗的显性甲状腺功能障碍患者发生 HF 的风险增加。此外，持续的亚临床甲状腺功能减退症与血清 TSH<0.1 或>10mU/l 的患者 HF 的发展相关。
甲状腺功能障碍患者必须及时识别和有效治疗心脏症状，因为适当治疗甲状腺功能障碍可能改善 HF 的预后。
